Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

12/11 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
28/26/28	SEK 0.8400	-0.59%	16,76,168
27/26/27	SEK 0.8450	+1.32%	8,87,200
26/26/26	SEK 0.8340	-1.18%	9,14,405
25/26/25	SEK 0.8440	+5.11%	13,17,058
24/26/24	SEK 0.8030	-1.95%	19,37,472

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm 09:30:00 28/08/2026 pm IST			5-day change	1st Jan Change
0.8400 ^SEK	-0.59%		+2.56%	+1.33%

20/08	Alzinova AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
20/08	RX Securities reiterates buy on Alzinova, justified value SEK 3.50	FW

Market Cap	17Cr 1.78Cr 1.53Cr 1.43Cr 1.31Cr 2.47Cr 169.72Cr 2.48Cr 6.64Cr 86Cr 6.67Cr 6.52Cr 284.08Cr	P/E 2026 *	-3.11x	P/E 2027 *	-2.21x
Enterprise Value	15Cr 1.61Cr 1.39Cr 1.3Cr 1.19Cr 2.24Cr 153.77Cr 2.24Cr 6.02Cr 78Cr 6.04Cr 5.91Cr 257.38Cr	EV / Sales 2026 *	4.92x	EV / Sales 2027 *	-
Free-Float	75.07%	Yield 2026 *	-	Yield 2027 *	-

20/08	Alzinova AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
20/08	RX Securities reiterates buy on Alzinova, justified value SEK 3.50	FW
20/08	Alzinova reports reduced operating loss	FW
20/08	Calendar Thursday, August 20	FW
24/06	Alzinova AB and Fujirebio Enter Letter of Intent for Potential Commercialization of Blood-Based Alzheimer?S Diagnostic Test	CI
24/06	Alzinova Inks Nonbinding Deal with Fujirebio for Potential Alzheimer's Blood-based Diagnostic Test	MT
24/06	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW
24/06	Alzinova signs non-binding letter of intent with Fujirebio on Alzheimer's diagnostics	FW
12/06	Alzinova raises SEK15.3m from warrants: underwriting not required	FW
08/06	Alzinova raises SEK 15.2 million before issuance costs	FW
26/05	Calendar Tuesday May 26	FW
25/05	Calendar Tuesday May 26	FW
21/05	Alzinova secures 80 percent of TO4 warrants	FW

20/08	RX Securities reiterates buy on Alzinova, justified value SEK 3.50	FW
24/06	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW
08/04	RX Securities sees potential upside for Alzinova from Alzheimer's diagnostic collaboration	FW
26/03	DNB Carnegie sees reduced financing risk for Alzinova, but partnership remains critical	FW
06/25/06	Alzinova gets fast track designation from US FDA	RE

Alzinova AB Share Price

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation : Alzinova AB

Chart: Alzinova AB

Latest news : Alzinova AB

Analysts' recommendations : Alzinova AB

Press Releases : Alzinova AB

Quotes and Performance

Price Extremes

Managers and Directors : Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

24/08	Alzinova: Diagnostics readout next, partner process delayed – Q2 review	AQ
20/08	Alzinova (Q2 Review): Capitalizing on diagnostics opportunities	AQ
20/08	Alzinova publishes interim report for the period January - June 2026	AQ
07/07	BioVal™ analysis of Alzinova's ALZ-101 – rNPV of SEK 7.1B	AQ
24/06	Alzinova: Newsflow update – diagnostic optionality and TO4 proceeds	AQ

1 day	-0.59%
1 week	+2.56%
Current month	-27.59%
1 month	-20.75%
3 months	+87.29%
6 months	+36.59%
Current year	+1.33%

1 week	0.77	0.9
1 month	0.75	1.23
Current year	0.38	1.61
1 year	0.38	2.28
3 years	0.38	4.62
5 years	0.38	8.7
10 years	0.38	44.9

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	01/10/2024
Anders Sandberg COO	Chief Operating Officer	54	17/08/2011
Erik Kullgren DFI	Director of Finance/CFO	57	27/03/2024

Director	Title	Age	Since
Clas Malmeström BRD	Director/Board Member	61	01/09/2015
Anders Waas BRD	Director/Board Member	69	01/01/2018
Carol Routledge BRD	Director/Board Member	-	01/01/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	-0.59%	+2.56%	-43.93%	-75.29%	1.8Cr
LONZA GROUP AG	-0.78%	-0.34%	+1.99%	+23.35%	5.11TCr
REVOLUTION MEDICINES, INC.	-6.00%	-1.82%	+446.48%	+527.28%	4.74TCr
IQVIA HOLDINGS INC.	-0.24%	+2.23%	+38.64%	+19.52%	4.32TCr
BEONE MEDICINES AG	-1.55%	-0.66%	+22.19%	+84.83%	4.24TCr
CELLTRION, INC.	-0.31%	-1.75%	+17.23%	+52.37%	3.32TCr
MEDPACE HOLDINGS, INC.	-1.79%	-1.96%	+26.86%	+131.18%	1.71TCr
ASCENDIS PHARMA A/S	-0.58%	-2.71%	-	-	1.64TCr
EUROFINS SCIENTIFIC SE	-0.88%	-0.63%	+11.05%	+29.54%	1.48TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.66%	+0.02%	+79.05%	+45.47%	1.42TCr
Average	-1.40%	+0.94%	+66.62%	+93.14%	2.8TCr
Weighted average by Cap.	-1.67%	+1.12%	+99.45%	+135.51%

	2026 *	2027 *
Net sales	3.14Cr 32.71L 28.18L 26.42L 24.12L 45.44L 31Cr 45.59L 1.22Cr 16Cr 1.23Cr 1.2Cr 52Cr	-
Net income	-44.5L -5L -4L -4L -3L -6L -4.44Cr -6L -17.36L -2.24Cr -17.43L -17.05L -7.43Cr	-7.7Cr -80.33L -69.22L -64.9L -59.25L -1.12Cr -77Cr -1.12Cr -3Cr -39Cr -3.02Cr -2.95Cr -128.51Cr
Net Debt	-1.6Cr -16.69L -14.38L -13.49L -12.31L -23.19L -16Cr -23.27L -62.43L -8.05Cr -62.67L -61.31L -27Cr	-1.9Cr -19.82L -17.08L -16.01L -14.62L -27.54L -19Cr -27.63L -74.13L -9.56Cr -74.42L -72.8L -32Cr